Cellectis (Alternext: ALCLS), the French genome engineering specialist, and Harvard Apparatus, a division of Harvard Bioscience, Inc. (Nasdaq: HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, have announced today that they have signed a license agreement that grants Harvard Apparatus the worldwide exclusive right to manufacture and sell, for research use, the full line of electroporation-based instruments acquired by Cellectis from CytoPulse in September of 2010. Cellectis retains all rights to the use of these products for its own research and development programs as well as in clinical trials and prophylactic or therapeutic procedures, for both humans and animals.
In the agreement, Cellectis will receive a payment of $1.3M from Harvard Apparatus. Cellectis will retain some annual licensing fees owed by existing and new customers. The CytoPulse instruments involved include DermaVax, OncoVet, Hybrimune, Cyto-LVT-S and Cyto-LVT-P.
"We are delighted to work with Harvard Apparatus on the distribution of this very efficient technology", declared Dirk Pollet, Chief Business Officer for Cellectis. "This deal provides Harvard Apparatus with an excellent new product line, while generating a robust revenue stream for Cellectis. In addition, it allows the technology to be made available to the research community to explore its potential."
Chane Graziano, CEO of Harvard Bioscience, commented, "This license significantly expands the cell biology research product line offered by Harvard Apparatus under the Warner Instruments and BTX brands. The technology is quite unique and patent protected and will provide our research customers with new tools to perform their electroporation and electrofusion experiments."
Microfluidic chips advance neurodegenerative disease research